Genscript Biotech Corp (Genscript) is a biotechnology company that provides life science research and applications solutions. The company’s product portfolio comprises antibodies, recombinant proteins, stable cell lines, molecular biology reagents, peptides and biochemicals, CRISPR Cas reagents and others. It provides peptide synthesis, genome editing, cell engineering, mutation and library solutions, preclinical drug development, biologics and manufacturing solutions. GenScript products find application in life science research, vaccine development, immunotherapy, COVID-19 and drug discovery and development. The company utilizes its proprietary gene synthesis technology in various fields from life science research through to translational biomedical development and industrial synthetic and cell therapeutic solutions. It operates in China, Singapore, Japan, the Netherlands, the UK and the US. Genscript is headquartered in Nanjing, Jiangsu, China.
Headquarters
China
Address
No. 28, Yongxi Road, Jiangning Science Park, Nanjing, Jiangsu
Website
www.genscript.com
Telephone
86 25 58897288
No of Employees
6,414
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
1548 (HKG)
Revenue (2022)
$625.7M
27.7%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
36.8%
(2022 vs 2021)
Market Cap*
$5.5B
Net Profit Margin (2022)
XYZ
50.5%
(2022 vs 2021)
* As of and is in US$
Genscript Biotech Corp premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| CRISPR | Antibody Discovery Service | cPass |
| Cas Nucleases | Cell Line Development Service | ProPlasmid |
| Ultra Nucleases | Plasmid CDMO Services | GMPro |
| XYZ | XYZ | |
| XYZ | XYZ | |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | New Products/Services | In September, the company added customized circular RNA and lipid nanoparticles (LNPs) formulation services. |
| 2023 | Contracts/Agreements | In August, the company entered into an agreement with T-MAXIMUM Biotech to enable the development of T-MAXIMUM's development CAR-T cell therapy using GenScript's CRISPR nucleic acid reagents. |
| 2023 | Corporate Changes/Expansions | In July, the company opened a state-of-the-art facility in Zhenjiang, Jiangsu, China. |
Competitor Comparison
| Key Parameters | Genscript Biotech Corp | BGI Genomics Co Ltd | Azenta Inc | Novogene Co Ltd | Absea Biotechnology Ltd |
|---|---|---|---|---|---|
| Headquarters | China | China | United States of America | China | China |
| City | Nanjing | Shenzhen | Chelmsford | Beijing | Beijing |
| State/Province | Jiangsu | Guangdong | Massachusetts | Beijing | Beijing |
| No. of Employees | 6,414 | 4,448 | 3,500 | 2,284 | - |
| Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Meng Jiange | Chairman | Executive Board | 2020 | 55 |
| Zhu Li | Director; Chief Strategy Officer | Executive Board | 2020 | 74 |
| Wang Ye | President; Director | Executive Board | 2015 | 54 |
| Zhang Fangliang | Director | Executive Board | 2022 | 58 |
| Wei Shiniu | Chief Financial Officer | Senior Management | 2020 | 43 |
| Non Dignissim Eros | Proin vel | Convallis | 2023 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2023 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2023 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward